CN102389595A - Non-drug treatment system for inactivation of HIV (human immunodeficiency virus) and other viruses - Google Patents
Non-drug treatment system for inactivation of HIV (human immunodeficiency virus) and other viruses Download PDFInfo
- Publication number
- CN102389595A CN102389595A CN2011101971822A CN201110197182A CN102389595A CN 102389595 A CN102389595 A CN 102389595A CN 2011101971822 A CN2011101971822 A CN 2011101971822A CN 201110197182 A CN201110197182 A CN 201110197182A CN 102389595 A CN102389595 A CN 102389595A
- Authority
- CN
- China
- Prior art keywords
- plasma
- blood
- deactivation
- inactivation
- treatment bag
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to a treatment system for carrying out autologous plasma virus inactivation for non-drug antivirus treatment on patients infected by lipid-enveloped viruses including HIV (human immunodeficiency virus) and the like caused by drug-resistant strains and variant strains. The treatment system comprises a plasma collector, a disposable separation and virus inactivation multi-purpose processor for collected plasma, an MB virus inactivator and an HHP virus inactivator, wherein the disposable separation and virus inactivation multi-purpose processor for collected plasma comprises a blood collector, a pipeline, a plasma separation cup, a lengthened plasma pipeline, a photochemical processing bag for pancake plasma collection and inactivation, a processing bag for tubular plasma collection and extra-high-pressure virus inactivation, an MB self-medicating pot, a puncture cap, a retaining clip, a blood filter, a pressure monitor, a saline water reinfusion needle and protection cap thereof, and an anticoagulant and protection cap thereof. The invention has the advantages of wide application range, good virus inactivation effect, wide spectrum of inactivated viruses, convenient operation process, high safety and efficiency and low cost, thereby being suitable to be popularized.
Description
Technical field
This is inactivation of virus therapy system such as a kind of non-medicine HIV for the present invention, belongs to infectious disease treatment, safe transfusion, blood products field.
Background technology
The Chinese full name of AIDS (AIDS): AIDS.It is the New Development viral infectious that is infected a kind of highly infective that causes by HIV (HIV).By the whole world known the harm of human catastrophe property decades, and various countries dropped into huge financial resources, material resources, science and technology and social resources developing drugs so far from 1981, developed vaccine.But because HIV has quite a lot of still lost own characteristic, do not find yet in the time range so far and can cure this sick ideal medicament and method fully, do not have the effectively vaccine of prevention yet.By 2010, China's accumulative total was reported HIV/AIDS37 ten thousand many cases, wherein dead 6.8 ten thousand examples.Ministry of Public Health is announced the infection total number of persons of estimating 740,000." cocktail " strengthened the Therapeutic Method that antiviral therapy is extensive use in the present world wide, and along with the prolongation of treatment time, the patient who receives treatment shows increasing practical problem.Especially, the toxic and side effects that medicine is serious, drug resistance that virus very easily produces and virus variation and immune evasion, high in addition medical expense is all felt patient and society and is difficult to bear.The situation of AIDS prevention and control is still severe, and new drug development and vaccine development all lag behind realities of the day far away.Global range expects in a hurry that all new Therapeutic Method and means, especially developing country will be placed on traditional medicine to attention and excavate single medicine and some other cheap efficacious therapy method.China's AIDS preventing and controlling work also proposes " will strengthen scientific research and on the basis of existing antiviral therapy, combine national conditions to accelerate the applied research of prophylactico-therapeutic measures, the wide receipts won, and uses by oneself ".This worldwide new special health problem of reply AIDS must be explored new treatment approaches and methods with the thinking of innovation fully.
Summary of the invention
The present invention provides inactivation of virus therapy system such as a kind of non-medicine HIV, adopts this system that lipid-coated virus infected patients such as HIV, HBV, HCV are carried out autologous plasma inactivation of virus treatment and handles, and directly causes virus such as HIV to be inactivated and reaches the purpose of treatment; The present invention is with low cost, safe and effective; Antiviral spectrum is wide, and is simple in structure, easy to operate; Good with the existing equipment compatibility, the suitable popularization.
The technical scheme that the present invention adopts is: inactivation of virus therapy system such as non-medicine HIV comprise: sampled plasma machine, disposable machine-collected plasma isolated viral deactivation multipurpose processor, MB inactivation of virus appearance, HHP inactivation of virus appearance, and wherein disposable machine-collected plasma isolated viral deactivation multipurpose processor comprises: hemostix; Pipeline, separating plasma cup, tubular plasma collection supertension inactivation treatment bag; Lengthening blood plasma pipeline, pie plasma collection deactivation photochemical treatment bag, MB is from the dosing fort; The puncture medicated cap, flow-stopping clip, blood filter; Pressure monitor; Saline feeds back pin and helmet, and anticoagulant and helmet is characterized in that connecting threeway after hemostix is provided with flow-stopping clip; Feeding back pipeline, the blood filter that pin and helmet and anticoagulant and helmet be provided with after the flow-stopping clip parallel connection with saline again is connected; Blood filter connects pressure monitor, and is connected with the separating plasma cup through pipeline, and the separating plasma cup is connected with tubular plasma collection supertension inactivation treatment bag, pie plasma collection deactivation photochemical treatment bag after connecting threeway through lengthening blood plasma pipeline; Wherein the preposition flow-stopping clip of tubular plasma collection supertension inactivation treatment bag links to each other with the threeway that lengthening blood plasma pipeline is connected; Pie plasma collection deactivation photochemical treatment bag adds respectively that through two threeways flow-stopping clip, flow-stopping clip and MB link to each other with the threeway that lengthening blood plasma pipeline is connected from the dosing fort, are provided with the puncture medicated cap respectively on tubular plasma collection supertension inactivation treatment bag and the pie plasma collection deactivation photochemical treatment bag.
The application of inactivation of virus therapy system such as non-medicine HIV of the present invention, when blood through hemostix flow ipe after the human body collection, inject anticoagulant through anticoagulant and helmet; This moment, saline fed back pin and helmet closedown of pipeline, and the blood that injects anticoagulant flows into the separating plasma cup through blood filter, the segment pipe of MB from the dosing fort was not set before closing tubular plasma collection supertension preposition pipeline of viral inactivation treatment bag and pie plasma collection deactivation photochemical treatment bag; Get into pie plasma collection deactivation photochemical treatment bag through being provided with MB from the passage of dosing fort through the effusive blood plasma of separating plasma cup, pie plasma collection deactivation photochemical treatment bag front end is provided with MB from the dosing fort, and the inside adds MB; Wherein MB belongs to the phenothiazines dyestuff; Be a kind of light-sensitive coloring agent, but the efficient inactivation lipid-containing envelope is viral, comprises retrovirus, herpesvirus, togavirus, yellow fever virus etc.; Plasma collection in pie plasma collection deactivation photochemical treatment bag is behind specified amount; Close the preposition flow-stopping clip of pie plasma collection deactivation photochemical treatment bag, pie plasma collection deactivation photochemical treatment bag is put into MB blood-plasma virus killing appearance and is carried out deactivation, and the sampled plasma machine feeds back blood cell automatically simultaneously; When blood cell feeds back residue 5-10ml; Suspend the feedback program, deactivation is unclamped the preposition flow-stopping clip of pie plasma collection deactivation photochemical treatment bag after accomplishing; Let the blood plasma after the deactivation feeds back program through opening the sampled plasma machine in the pie plasma collection deactivation photochemical treatment bag; Carry out human body and feed back, the course of treatment, number of times can carry out repeatedly blood-plasma virus killing according to patient's situation, reached therapeutic purposes.
When blood through hemostix flow ipe after the human body collection, inject anticoagulant through anticoagulant and helmet; This moment, saline fed back pin and helmet closedown of pipeline, and the blood that injects anticoagulant flows into the separating plasma cup through blood filter, closes the preposition flow-stopping clip of pie plasma collection deactivation photochemical treatment bag; Get into tubular plasma collection supertension inactivation treatment bag through the effusive blood plasma of separating plasma cup, capacity can be at 200ml-800ml, and blood plasma flows into tubular plasma collection supertension inactivation treatment bag through pipeline; The blood plasma harvester feeds back blood cell automatically after reaching quantitative blood plasma, cuts off pipeline then and carries out and fuse, and tubular plasma collection supertension inactivation treatment bag is put into HHP blood-plasma virus killing appearance carry out inactivation of virus; Blood plasma is under 5 ℃～15 ℃, 250～350MPa condition after pressurized treatments 5-10 minute; Pressure release is made zero, and pressurization pressure release circulation 1-3 time is after the blood plasma process HHP blood-plasma virus killing appearance deactivation in the tubular plasma collection supertension inactivation treatment bag; Close the anticoagulant pipeline; Blood plasma after the deactivation can feed back pin through saline and feed back patient, also can feed back human body through other liquid roads, reaches therapeutic purposes.Lipid-containing envelope viruses such as possibly having the HIV that comprises persister and variant, HBV, HCV in the blood plasma is inactivated, reaches the therapeutic purposes that alleviate virus loads and protection CD4 immunocyte and immunologic reconstitution in the blood circulation.Simultaneously, this therapy system also has effective deactivation to nonenveloped viruses such as EMCV.
The present invention has obtained following beneficial effect: adopt inactivation of virus therapy system such as non-medicine HIV; Can the sampled plasma machine and the blood-plasma virus killing apparatus of prior art be realized separating plasma MB Automatic Dosing with processor and the combination of fitting operation program chains that the inventor sets up; MB inactivation of virus and HHP supertension inactivation of virus, blood plasma feeds back and carries out totally enclosed type respectively or be interrupted closed processing after the deactivation.Patient HIV/AIDS is treated, can make interior HIV virus structure of patient's blood plasma and function directly destroyed inactivation and effectively alleviate the HIV load in patient's blood circulation at short notice.Virus is lost infect and active ability of duplicating, reach the purpose of antiviral and immunization therapy.This therapy is applicable to each period, particularly early treatment of HIV infection, does not have toxic and side effects, does not produce persister, and is effective equally to variant, and technology maturation, cost, the suitable popularization.
Description of drawings
Fig. 1 is inactivation of virus therapy system structural representations such as non-medicine HIV, wherein.
The 1-hemostix, 2-pipeline, 3-separating plasma cup, 4-tubular plasma collection supertension inactivation treatment bag; 5-lengthening blood plasma pipeline, 6-pie plasma collection deactivation photochemical treatment bag, 7-MB is from the dosing fort; The 8-medicated cap that punctures, 9-flow-stopping clip, 10-blood filter; The 11-pressure monitor, 12-saline feeds back pin and helmet, 13-anticoagulant and helmet.
The specific embodiment
Below in conjunction with accompanying drawing the present invention is done a detailed description:
Embodiment 1: when blood through hemostix flow ipe after the human body collection, inject anticoagulant through anticoagulant and helmet; This moment, saline fed back pin and helmet closedown of pipeline; The blood that injects anticoagulant flows into the separating plasma cup through blood filter; Before closing tubular plasma collection supertension preposition pipeline of viral inactivation treatment bag and pie plasma collection deactivation photochemical treatment bag the segment pipe of MB from the dosing fort is not set; Get into pie plasma collection deactivation photochemical treatment bag through being provided with MB from the passage of dosing fort through the effusive blood plasma of separating plasma cup, pie plasma collection deactivation photochemical treatment bag front end is provided with MB from the dosing fort, and the inside adds MB; Wherein MB belongs to the phenothiazines dyestuff; Be a kind of light-sensitive coloring agent, but the efficient inactivation lipid-containing envelope is viral, comprises lipid-coated virus such as HIV, HBV, HCV and herpesvirus, togavirus, yellow fever virus etc.After the blood plasma in the pie plasma collection deactivation photochemical treatment bag was input to specified amount, the plasma collection in pie plasma collection deactivation photochemical treatment bag was closed the preposition flow-stopping clip of pie plasma collection deactivation photochemical treatment bag behind specified amount; Pie plasma collection deactivation photochemical treatment bag is put into MB blood-plasma virus killing appearance and is carried out deactivation; The sampled plasma machine feeds back blood cell automatically simultaneously, when blood cell feeds back residue 5-10ml, suspends the feedback program; After deactivation is accomplished; Unclamp the preposition flow-stopping clip of pie plasma collection deactivation photochemical treatment bag, let the blood plasma after the deactivation feeds back program through opening the sampled plasma machine in the pie plasma collection deactivation photochemical treatment bag, carry out human body and feed back; The course of treatment, number of times can carry out repeatedly blood-plasma virus killing according to patient's situation, reached therapeutic purposes.
Embodiment 2: when blood through hemostix flow ipe after the human body collection, inject anticoagulant through anticoagulant and helmet; This moment, saline fed back pin and helmet closedown of pipeline, and the blood that injects anticoagulant flows into the separating plasma cup through blood filter, closes the preposition flow-stopping clip of pie plasma collection deactivation photochemical treatment bag; Get into tubular plasma collection supertension inactivation treatment bag through the effusive blood plasma of separating plasma cup, capacity can be at 200ml-800ml, and blood plasma flows into tubular plasma collection supertension inactivation treatment bag through pipeline; The blood plasma harvester feeds back blood cell automatically after reaching quantitative blood plasma, cuts off pipeline then and carries out and fuse, and tubular plasma collection supertension inactivation treatment bag is put into HHP blood-plasma virus killing appearance carry out inactivation of virus; Blood plasma is under 5 ℃～15 ℃, 250～350MPa condition after pressurized treatments 5-10 minute; Pressure release is made zero, and pressurization pressure release circulation 1-3 time is after the blood plasma process HHP blood-plasma virus killing appearance deactivation in the tubular plasma collection supertension inactivation treatment bag; Close the anticoagulant pipeline; Blood plasma after the deactivation can feed back pin through saline and feed back patient, also can feed back human body through other liquid roads, reaches therapeutic purposes.Lipid-containing envelope viruses such as possibly having the HIV that comprises persister and variant, HBV, HCV in the blood plasma is inactivated, reaches the therapeutic purposes that alleviate virus loads and protection CD4 immunocyte and immunologic reconstitution in the blood circulation.Simultaneously, this therapy system also has effective deactivation to nonenveloped viruses such as EMCV.
Embodiment 3: can also can be used in combination through carrying out deactivation in appearance deactivation of HHP blood-plasma virus killing and the MB blood-plasma virus killing appearance, carry out dual inactivation of virus.
The present invention also has deactivation to nonenveloped virus except that lipid-coated virus such as HIV.As reducing greater than 7.0log TCID after EMCV, 300MPa, the 3Min deactivation.So the opportunistic infection due to born of the same parents' gizzard virus etc. infected are the effective therapeutical effect of tool also.
Claims (7)
1. inactivation of virus therapy system such as non-medicine HIV comprise: sampled plasma machine, disposable machine-collected plasma isolated viral deactivation multipurpose processor, MB inactivation of virus appearance, HHP inactivation of virus appearance, and wherein disposable machine-collected plasma isolated viral deactivation multipurpose processor comprises: hemostix; Pipeline, separating plasma cup, tubular plasma collection supertension inactivation treatment bag; Lengthening blood plasma pipeline, pie plasma collection deactivation photochemical treatment bag, MB is from the dosing fort; The puncture medicated cap, flow-stopping clip, blood filter; Pressure monitor; Saline feeds back pin and helmet, and anticoagulant and helmet is characterized in that connecting threeway after hemostix is provided with flow-stopping clip; Feeding back pipeline, the blood filter that pin and helmet and anticoagulant and helmet be provided with after the flow-stopping clip parallel connection with saline again is connected; Blood filter connects pressure monitor, and is connected with the separating plasma cup through pipeline, and the separating plasma cup is connected with tubular plasma collection supertension inactivation treatment bag, pie plasma collection deactivation photochemical treatment bag after connecting threeway through lengthening blood plasma pipeline; Wherein the preposition flow-stopping clip of tubular plasma collection supertension inactivation treatment bag links to each other with the threeway that lengthening blood plasma pipeline is connected; Pie plasma collection deactivation photochemical treatment bag adds respectively that through two threeways flow-stopping clip, flow-stopping clip and MB link to each other with the threeway that lengthening blood plasma pipeline is connected from the dosing fort, are provided with the puncture medicated cap respectively on tubular plasma collection supertension inactivation treatment bag and the pie plasma collection deactivation photochemical treatment bag.
2. according to the application of inactivation of virus therapy system such as the said non-medicine HIV of claim 1, it is characterized in that: blood injects anticoagulant through hemostix flow ipe after the human body collection through anticoagulant and helmet; This moment, saline fed back pin and helmet closedown of pipeline, and the blood that injects anticoagulant flows into the separating plasma cup through blood filter, the segment pipe of MB from the dosing fort was not set before closing tubular plasma collection supertension preposition pipeline of viral inactivation treatment bag and pie plasma collection deactivation photochemical treatment bag; Get into pie plasma collection deactivation photochemical treatment bag through being provided with MB from the passage of dosing fort through the effusive blood plasma of separating plasma cup, pie plasma collection deactivation photochemical treatment bag front end is provided with MB from the dosing fort, and the inside adds MB; Wherein MB belongs to the phenothiazines dyestuff; Be a kind of light-sensitive coloring agent, but the efficient inactivation lipid-containing envelope is viral, comprises HIV, HBV, HCV and herpesvirus, togavirus, yellow fever virus etc.; Plasma collection in pie plasma collection deactivation photochemical treatment bag is behind specified amount; Close the preposition flow-stopping clip of pie plasma collection deactivation photochemical treatment bag, pie plasma collection deactivation photochemical treatment bag is put into MB blood-plasma virus killing appearance and is carried out deactivation, and the sampled plasma machine feeds back blood cell automatically simultaneously; When blood cell feeds back residue 5-10ml; Suspend the feedback program, deactivation is unclamped the preposition flow-stopping clip of pie plasma collection deactivation photochemical treatment bag after accomplishing; Let the blood plasma after the deactivation feeds back program through opening the sampled plasma machine in the pie plasma collection deactivation photochemical treatment bag; Carry out human body and feed back, the course of treatment, number of times can carry out repeatedly blood-plasma virus killing according to patient's situation, reached therapeutic purposes.
3. according to inactivation of virus therapy system such as claim 1 and 2 described non-medicine HIV; It is characterized in that: pie plasma collection deactivation photochemical treatment bag is provided with the puncture medicated cap; Blood plasma after carrying out deactivation needs to increase the treatment treating capacity after feeding back human body; Can add MB through the puncture medicated cap, reuse pie plasma collection deactivation photochemical treatment bag and carry out above flow process.
4. according to inactivation of virus therapy system such as claims 1 described non-medicine HIV, it is characterized in that: blood injects anticoagulant through hemostix flow ipe after the human body collection through anticoagulant and helmet; This moment, saline fed back pin and helmet closedown of pipeline; The blood that injects anticoagulant flows into the separating plasma cup through blood filter, closes the preposition flow-stopping clip of pie plasma collection deactivation photochemical treatment bag, gets into tubular plasma collection supertension inactivation treatment bag through the effusive blood plasma of separating plasma cup; Capacity can be at 200ml-800ml; Blood plasma flows into tubular plasma collection supertension inactivation treatment bag through pipeline, and the blood plasma harvester feeds back blood cell automatically after reaching quantitative blood plasma, cuts off pipeline then and carries out and fuse; Tubular plasma collection supertension inactivation treatment bag is put into HHP blood-plasma virus killing appearance carry out inactivation of virus; After the blood plasma process HHP blood-plasma virus killing appearance deactivation in the tubular plasma collection supertension inactivation treatment bag, close the anticoagulant pipeline, the blood plasma after the deactivation can feed back pin through saline and feed back patient; Also can feed back human body, reach therapeutic purposes through other liquid roads.
5. according to the application of inactivation of virus therapy system such as claim 1 and 4 said non-medicine HIV; It is characterized in that: tubular plasma collection supertension inactivation treatment bag is put into HHP blood-plasma virus killing appearance; Blood plasma is under 5 ℃～15 ℃, 250～350MPa condition after pressurized treatments 5-10 minute; Pressure release is made zero, and pressurization pressure release circulation 1-3 time is inactivated lipid-containing envelope viruses such as possibly having the HIV that comprises persister and variant, HBV, HCV in the blood plasma; Then the blood plasma behind the inactivation of virus is fed back to human body, reach the therapeutic purposes that alleviate virus loads in the blood circulation and protection CD4 immunocyte and immunologic reconstitution.Simultaneously, this therapy system also has effective deactivation to nonenveloped viruses such as EMCV.
6. plasma collection bags such as tubular plasma collection supertension inactivation treatment bag according to claim 1, pie plasma collection deactivation photochemical treatment bag are one or more plasma collection bags.
7. according to claims 1-6, can also can be used in combination through carrying out deactivation in appearance deactivation of HHP blood-plasma virus killing and the MB blood-plasma virus killing appearance, carry out dual inactivation of virus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110197182.2A CN102389595B (en) | 2011-07-14 | 2011-07-14 | Non-drug treatment system for inactivation of HIV (human immunodeficiency virus) and other viruses |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110197182.2A CN102389595B (en) | 2011-07-14 | 2011-07-14 | Non-drug treatment system for inactivation of HIV (human immunodeficiency virus) and other viruses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102389595A true CN102389595A (en) | 2012-03-28 |
| CN102389595B CN102389595B (en) | 2014-09-24 |
Family
ID=45857058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110197182.2A Active CN102389595B (en) | 2011-07-14 | 2011-07-14 | Non-drug treatment system for inactivation of HIV (human immunodeficiency virus) and other viruses |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102389595B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104174042A (en) * | 2014-08-29 | 2014-12-03 | 郑州飞龙医疗设备有限公司 | Ultrahigh-pressure inactivating method for pathogens in biological products and applications thereof |
| CN104399135A (en) * | 2014-11-20 | 2015-03-11 | 上海市血液中心 | Processing device for plasma virus inactivation |
| CN107715211A (en) * | 2017-11-01 | 2018-02-23 | 杭州蕙新医疗科技有限公司 | A kind of plasma exchange loading photochemical virus inactivation device and its application apparatus |
| CN108498795A (en) * | 2018-03-22 | 2018-09-07 | 耿艳春 | The one-step preparation process of therapeutic type drug resistance AIDS self-plasma virus deactivation vaccine |
| CN112386717A (en) * | 2020-12-11 | 2021-02-23 | 西安市中心医院 | Disposable blood virus inactivating device |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1025872A2 (en) * | 1999-02-02 | 2000-08-09 | Fresenius HemoCare GmbH | Tube set for a cell separator for separating blood into its components and cell separator using the tube set |
| CN2411003Y (en) * | 2000-03-30 | 2000-12-20 | 孙锦山 | Channel of dispersable mechanical blood sampling erythrocye and plasma separator |
| CN1240460C (en) * | 1999-09-03 | 2006-02-08 | 巴克斯特国际公司 | Blood processing procedures with related sensing procedures |
| CN2827384Y (en) * | 2005-05-18 | 2006-10-18 | 李金城 | Disposable device for plasma-taking and virus-inactivation separator |
| WO2006110470A1 (en) * | 2005-04-08 | 2006-10-19 | Mission Medical, Inc. | Centrifuge for blood processing systems |
| PT933090E (en) * | 1998-01-30 | 2006-12-29 | Maco Pharma Internat Gmbh | Blood bag system for the inactivation of pathogens in blood, blood components and plasma |
-
2011
- 2011-07-14 CN CN201110197182.2A patent/CN102389595B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT933090E (en) * | 1998-01-30 | 2006-12-29 | Maco Pharma Internat Gmbh | Blood bag system for the inactivation of pathogens in blood, blood components and plasma |
| EP1025872A2 (en) * | 1999-02-02 | 2000-08-09 | Fresenius HemoCare GmbH | Tube set for a cell separator for separating blood into its components and cell separator using the tube set |
| CN1240460C (en) * | 1999-09-03 | 2006-02-08 | 巴克斯特国际公司 | Blood processing procedures with related sensing procedures |
| CN2411003Y (en) * | 2000-03-30 | 2000-12-20 | 孙锦山 | Channel of dispersable mechanical blood sampling erythrocye and plasma separator |
| WO2006110470A1 (en) * | 2005-04-08 | 2006-10-19 | Mission Medical, Inc. | Centrifuge for blood processing systems |
| CN2827384Y (en) * | 2005-05-18 | 2006-10-18 | 李金城 | Disposable device for plasma-taking and virus-inactivation separator |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104174042A (en) * | 2014-08-29 | 2014-12-03 | 郑州飞龙医疗设备有限公司 | Ultrahigh-pressure inactivating method for pathogens in biological products and applications thereof |
| CN104399135A (en) * | 2014-11-20 | 2015-03-11 | 上海市血液中心 | Processing device for plasma virus inactivation |
| CN107715211A (en) * | 2017-11-01 | 2018-02-23 | 杭州蕙新医疗科技有限公司 | A kind of plasma exchange loading photochemical virus inactivation device and its application apparatus |
| CN108498795A (en) * | 2018-03-22 | 2018-09-07 | 耿艳春 | The one-step preparation process of therapeutic type drug resistance AIDS self-plasma virus deactivation vaccine |
| CN112386717A (en) * | 2020-12-11 | 2021-02-23 | 西安市中心医院 | Disposable blood virus inactivating device |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102389595B (en) | 2014-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102389595B (en) | Non-drug treatment system for inactivation of HIV (human immunodeficiency virus) and other viruses | |
| Lelie et al. | Inactivation of 12 viruses by heating steps applied during manufacture of a hepatitis B vaccine | |
| WO1987006119A1 (en) | Anti-pathogenic blood collection system and method | |
| CN201020070Y (en) | Full-automatic self-plasma virus deactivation therapeutic equipment | |
| CN202236530U (en) | Leucocyte removal blood bag capable of inactivating viruses | |
| CN2827384Y (en) | Disposable device for plasma-taking and virus-inactivation separator | |
| Skinner et al. | Overcoming the immune privilege of B cell follicles to cure HIV-1 infection | |
| FI105453B (en) | A method of producing a vaccine against HIV retroviral infection | |
| Rawal et al. | Leukocyte filtration removes infectious particulate debris but not free virus derived from experimentally lysed HIV-infected cells | |
| US11197924B2 (en) | Photochemical preparation method for autologous plasma inactivated vaccine for treating AIDS | |
| CN201271255Y (en) | Blood bag with device for inactivating and filtering blood plasma virus | |
| CN2803274Y (en) | Disposable machine extrating and blood plasma virus deactivating hemostix | |
| JP3172373B2 (en) | A device that inactivates or reduces bacteria or viruses in human blood | |
| CN215840804U (en) | Disposable machine blood sampling purifying treatment pipeline | |
| CN205569428U (en) | Take transfusion system of syringe needle cutterbar | |
| CN102727523A (en) | Medicine possessing anti-HIV latent effect and its application | |
| CN204468966U (en) | The hemodialysis puncture of internal arteriovenous fistula pin improved | |
| Abdul-Rahman | Is There Any Modern and Efficient Cure of nCOVID-19 | |
| CN209679204U (en) | Automatic plucking machine cart | |
| CN101002949A (en) | HIV-Env gene DNA allosterism recombination envelope protein antigen for immunoresponsiveness of anti-HIV test and method | |
| Kiene et al. | Hepatitis, HIV, and the dermatologist: a risk review | |
| Rarick et al. | Intravenous immune globulin use in patients with human immunodeficiency virus-related thrombocytopenia who require dental extraction. | |
| CN202236536U (en) | Multi-purpose processor for disposable machine collected blood plasma separation and viral inactivation | |
| McCarthy | Further clues emerge for strategies to attack HIV | |
| CN104815052A (en) | Chinese medicinal composition for resisting influenza virus infection and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Non-drug treatment system for inactivation of HIV (human immunodeficiency virus) and other viruses Effective date of registration: 20160624 Granted publication date: 20140924 Pledgee: Henan SME Investment Guarantee Limited by Share Ltd Pledgor: Zhengzhou Feilong Medical Equipment Co., Ltd. Registration number: 2016990000495 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20170728 Granted publication date: 20140924 Pledgee: Henan SME Investment Guarantee Limited by Share Ltd Pledgor: Zhengzhou Feilong Medical Equipment Co., Ltd. Registration number: 2016990000495 |